Design, Synthesis and Antitumor Activity Evaluation Research of Novel 2,4,6-Substituted Pyrimidine Derivatives
Yang Zhang,Luye Zhang,Jikuan Wang,Limin Liu,Tao Wang,Na Li,Zhengjie Wang,Xiujuan Liu,Yaxin Chen,Danlin Zhao,Jiaxin Zheng,Lihong Shan,Hongmin Liu,Qiurong Zhang
DOI: https://doi.org/10.6023/cjoc202007067
2021-01-01
Chinese Journal of Organic Chemistry
Abstract:With the expectation to find out novel and effective anti-tumor agents, a series of novel 2,4,6-substituted pyrimidine derivatives were synthesized and evaluated for their anti-tumor activity against four human cancer cells [SW-620 (human colon cancer cells), PC-3 (human prostate cancer cells), A549 (Human non-small cell lung cancer cells), MGC-803 (human gastric cancer cells)] using methyl thiazolyl tetrazolium (MTT) assay. Among tested compounds, N-((4-ethylphenyl)carbamoyl)-2-((4-(p-tolylamino)-6-(trifluoromethyl)pyrimidin-2-yl)thio)acetamide (5i), 2-((4-((4-ethoxyphenyl)amino)-6-(trifluoromethyl)pyrimidin- 2-yl)thio)-N-((4-ethylphenyl)carbamoyl)acetamide (5o) and N-((4-ethylphenyl)carbamoyl)-2-((4-((4-methoxyphenyl)amino)-6-(trifluoromethyl)pyrimidin-2-yl)thio)acetamide (5r) displayed strong antiproliferative activity on 4 tested cancer cell lines. In particular, compound 5r has the highest inhibitive activity, and possessed the lowest IC50 value of 1.46 mu mol/L towards SW-620 cells. Further mechanism research shows that compound 5r induces SW-620 apoptosis, arrests cell cycle at S phase. Molecular docking reveals that 5r can bind well to the active site of epidermal growth factor receptor (EG-FR), and may be considered as a promising compound amenable for further investigation for the development of new anticancer agents.